Symbol="APLS"
AssetType="Common Stock"
Name="Apellis Pharmaceuticals Inc"
Description="Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts."
CIK="1492422"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="6400 WESTWIND WAY, SUITE A, CRESTWOOD, KY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="9840616000"
EBITDA="-639102016"
PERatio="None"
PEGRatio="None"
BookValue="3.547"
DividendPerShare="0"
DividendYield="0"
EPS="-6.14"
RevenuePerShareTTM="0.962"
ProfitMargin="0"
OperatingMarginTTM="-6.05"
ReturnOnAssetsTTM="-0.377"
ReturnOnEquityTTM="-1.581"
RevenueTTM="105887000"
GrossProfitTTM="69786000"
DilutedEPSTTM="-6.14"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="2.118"
AnalystTargetPrice="102.08"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="51.26"
PriceToBookRatio="17.67"
EVToRevenue="42.79"
EVToEBITDA="-8.03"
Beta="1.268"
num_52WeekHigh="94.75"
num_52WeekLow="42.15"
num_50DayMovingAverage="88.23"
num_200DayMovingAverage="66.53"
SharesOutstanding="116457000"
DividendDate="None"
ExDividendDate="None"
symbol="APLS"
open="86.13"
high="86.87"
low="84.30"
price="84.50"
volume="1191749.00"
latest_trading_day="2023-07-14"
previous_close="85.98"
change="-1.48"
change_percent="-1.7213%"
aroon_positive_momentum_days="100"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="100"
Volume_recent_avg="1795491"
Change_recent_avg="0.27"
Delta_recent_avg="2.9"
Variance_recent_avg="1.45"
Change_ratio_recent_avg="0.31"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="100"
Aroon_momentum_negative="0"
image_negative_thumbnail_id_1="1104"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0137.jpeg"
image_negative_thumbnail_id_2="1147"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0180.jpeg"
image_neutral_thumbnail_id_1="561"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0038.jpeg"
image_neutral_thumbnail_id_2="553"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0046.jpeg"
image_positive_thumbnail_id_1="651"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0057.jpeg"
image_positive_thumbnail_id_2="671"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0037.jpeg"
image_professor_thumbnail_id_1="1185"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
image_professor_thumbnail_id_2="1200"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
